Content about Duloxetine

January 29, 2013
Eli Lilly reports 1% Q4 decline from Zyprexa patent expiration

Eli Lilly and Company reported that its fourth quarter revenue for the period ended Dec. 31 declined 1% to $6 billion because of its Zyprexa patent expiration. Full-year 2012 revenue declined 7% to $22.6 billion.

INDIANAPOLIS — Eli Lilly and Company on Tuesday reported that its fourth quarter revenue for the period ended Dec. 31 declined 1% to $6 billion because of its Zyprexa patent expiration. Full-year 2012 revenue declined 7% to $22.6 billion.

July 6, 2012
Lilly gains U.S. pediatric exclusivity for Cymbalta

Eli Lilly announced that it has met Food and Drug Administration requirements for pediatric exclusivity for its antidepressant medication.

INDIANAPOLIS — Eli Lilly announced that it has met Food and Drug Administration requirements for pediatric exclusivity for its antidepressant medication.

Based on this decision by the FDA, Lilly has gained an additional six months of U.S. market exclusivity for Cymbalta (duloxetine hydrochloride), which now will expire in December 2013.

April 28, 2011
Court upholds Lilly's patent for Cymbalta

Drug maker Eli Lilly will get at least two more years of patent exclusivity on a drug used to treat depression, anxiety and pain resulting from diabetic neuropathy and fibromyalgia, thanks to a court order issued Wednesday.

INDIANAPOLIS — Drug maker Eli Lilly will get at least two more years of patent exclusivity on a drug used to treat depression, anxiety and pain resulting from diabetic neuropathy and fibromyalgia, thanks to a court order issued Wednesday.

The U.S. District Court for the Southern District of Indiana ruled to forbid Wockhardt and other generic drug companies from selling generic versions of Cymbalta (duloxetine hydrochloride) until patent protection expires, which is expected to occur in June 2013.

November 29, 2010
FDA tentatively approves Sun's generic Cymbalta

A generic drug maker announced that the Food and Drug Administration has granted tentative approval for its version of a popular antidepressant.

MUMBAI, India — A generic drug maker announced that the Food and Drug Administration has granted tentative approval for its version of a popular antidepressant.

Sun Pharmaceutical Industries said the FDA approved its duloxetine hydrochloride delayed-release capsules in 20-mg, 30-mg and 60-mg strengths. The capsules are a generic version of Eli Lilly's Cymbalta, which is indicated to treat major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain.

November 4, 2010
FDA approves Cymbalta for treating chronic musculoskeletal pain

The Food and Drug Administration has approved a new usage for a drug used to...

INDIANAPOLIS The Food and Drug Administration has approved a new usage for a drug used to treat depression and pain.

Eli Lilly said Thursday that the FDA had approved Cymbalta (duloxetine hydrochloride) for treating chronic musculoskeletal pain. This is the fifth indication for which the agency has approved Cymbalta, after major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain and fibromyalgia, Lilly said.

August 19, 2010
FDA recommends expanding the use of Cymbalta

A Food and Drug Administration advisory committee has voted to recommend expanding the use of...

BETHESDA, Md. A Food and Drug Administration advisory committee has voted to recommend expanding the use of an Eli Lilly & Co. pain drug, the drug maker said Thursday.

Lilly said the FDA’s Anesthetic and Life Support Drugs Advisory Committee voted to recommend approval of Cymbalta (duloxetine hydrochloride) as a treatment for chronic lower back pain, though it did not support the drug as a treatment for chronic pain due to osteoarthritis. The drug currently is approved for treating diabetic peripheral neuropathic pain and fibromyalgia.

May 31, 2010
Consumer Reports survey: Antidepressant use on the rise

A new Consumer Reports health survey found that nearly 80% of respondents seeking treatment for...

March 17, 2010
Lilly comments on drug theft at Connecticut facility

Drugs stolen from an Eli Lilly warehouse in Connecticut Sunday unlikely are to make it...

February 2, 2010
Lilly: Study shows Cymbalta 'signficantly' reduces back pain

A pain drug made by Eli Lilly & Co. “significantly” reduced chronic low back pain...

January 24, 2010
Decision Resources: Fibromyalgia drug may have firm grasp on market through 2018

A hypothetical fibromyalgia drug that improved sleeping quality better than the top-selling drugs on the...

January 12, 2010
FDA issues warning letters to drug companies for misleading ads

Four drug companies have received warnings from the Food and Drug Administration in the last...